PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN

Translated title of the contribution: Photodynamic therapy of experimental intraocular melanoma using benzoporphyrin lipoprotein

U. Schmidt-Erfurth, T. Hasan, Thomas J Flotte, E. Gragoudas, R. Birngruber

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) with its potential for precise localization and absence of severe side effects such as radiation retinopathy may be particularly appropriate for the treatment of intraocular tumors. Benzoporphyrin (BPD), a potent photosensitizer currently in clinical trial, absorbs light at 692 nm, thus allowing sufficient tissue penetration due to minor light absorption in melanin and hemoglobin. The efficiency and selectivity of BPD are significantly pronounced through preassociation with low-density lipoprotein (LDL), since proliferating cells exhibit an increased metabolism of lipoproteins. As an experimental model Greene's melanomas were implanted either into the iris or choroid of albino rabbits. Irradiation at a radiation energy of 80 for iris and 100 J/cm2 for choroidal tumors 3 h after the i.v. injection of BPD-LDL (2 mg/kg) was administered via a laser arrangement with argon-pumped dye-laser, using the slit-lamp. Angiographies and LM/EM histologies were done immediately, and 1, 3, and 14-21 days post-exposure. All 16 treated tumors demonstrated complete regression with a remaining avascular, fibrotic scar. Immediate vascular occlusion within the tumor was seen angiographically, suggesting a direct vascular mechanism. Histologically, two primary mechanisms could be detected: destruction of neovascular endothelial cells and intracellular tumor cell damage. These results indicate that PDT using BPD-LDL complexes may provide an efficient and selective modality for the management of intraocular neoplasms. The availability of new and potent photosensitizers may also lead to broader clinical applications.

Original languageGerman
Pages (from-to)348-356
Number of pages9
JournalOphthalmologe
Volume91
Issue number3
StatePublished - 1994
Externally publishedYes

Fingerprint

Experimental Melanomas
Photochemotherapy
Lipoproteins
LDL Lipoproteins
Neoplasms
Photosensitizing Agents
Iris
Blood Vessels
Radiation
Dye Lasers
Choroid
Argon
Melanins
Cicatrix
Melanoma
Histology
Angiography
Hemoglobins
Lasers
Theoretical Models

Keywords

  • benzoporphyrin
  • intraocular melanoma
  • low-density lipoprotein
  • photodynamic therapy
  • selective delivery

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Schmidt-Erfurth, U., Hasan, T., Flotte, T. J., Gragoudas, E., & Birngruber, R. (1994). PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN. Ophthalmologe, 91(3), 348-356.

PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN. / Schmidt-Erfurth, U.; Hasan, T.; Flotte, Thomas J; Gragoudas, E.; Birngruber, R.

In: Ophthalmologe, Vol. 91, No. 3, 1994, p. 348-356.

Research output: Contribution to journalArticle

Schmidt-Erfurth, U, Hasan, T, Flotte, TJ, Gragoudas, E & Birngruber, R 1994, 'PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN', Ophthalmologe, vol. 91, no. 3, pp. 348-356.
Schmidt-Erfurth, U. ; Hasan, T. ; Flotte, Thomas J ; Gragoudas, E. ; Birngruber, R. / PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN. In: Ophthalmologe. 1994 ; Vol. 91, No. 3. pp. 348-356.
@article{ff7ba0f1b7cb45a49af794a3593165f1,
title = "PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN",
abstract = "Photodynamic therapy (PDT) with its potential for precise localization and absence of severe side effects such as radiation retinopathy may be particularly appropriate for the treatment of intraocular tumors. Benzoporphyrin (BPD), a potent photosensitizer currently in clinical trial, absorbs light at 692 nm, thus allowing sufficient tissue penetration due to minor light absorption in melanin and hemoglobin. The efficiency and selectivity of BPD are significantly pronounced through preassociation with low-density lipoprotein (LDL), since proliferating cells exhibit an increased metabolism of lipoproteins. As an experimental model Greene's melanomas were implanted either into the iris or choroid of albino rabbits. Irradiation at a radiation energy of 80 for iris and 100 J/cm2 for choroidal tumors 3 h after the i.v. injection of BPD-LDL (2 mg/kg) was administered via a laser arrangement with argon-pumped dye-laser, using the slit-lamp. Angiographies and LM/EM histologies were done immediately, and 1, 3, and 14-21 days post-exposure. All 16 treated tumors demonstrated complete regression with a remaining avascular, fibrotic scar. Immediate vascular occlusion within the tumor was seen angiographically, suggesting a direct vascular mechanism. Histologically, two primary mechanisms could be detected: destruction of neovascular endothelial cells and intracellular tumor cell damage. These results indicate that PDT using BPD-LDL complexes may provide an efficient and selective modality for the management of intraocular neoplasms. The availability of new and potent photosensitizers may also lead to broader clinical applications.",
keywords = "benzoporphyrin, intraocular melanoma, low-density lipoprotein, photodynamic therapy, selective delivery",
author = "U. Schmidt-Erfurth and T. Hasan and Flotte, {Thomas J} and E. Gragoudas and R. Birngruber",
year = "1994",
language = "German",
volume = "91",
pages = "348--356",
journal = "Der Ophthalmologe",
issn = "0941-293X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - PHOTODYNAMISCHE THERAPIE EXPERIMENTELLER, INTRAOKULARER TUMOREN MIT BENZOPORPHYRIN-LIPOPROTEIN

AU - Schmidt-Erfurth, U.

AU - Hasan, T.

AU - Flotte, Thomas J

AU - Gragoudas, E.

AU - Birngruber, R.

PY - 1994

Y1 - 1994

N2 - Photodynamic therapy (PDT) with its potential for precise localization and absence of severe side effects such as radiation retinopathy may be particularly appropriate for the treatment of intraocular tumors. Benzoporphyrin (BPD), a potent photosensitizer currently in clinical trial, absorbs light at 692 nm, thus allowing sufficient tissue penetration due to minor light absorption in melanin and hemoglobin. The efficiency and selectivity of BPD are significantly pronounced through preassociation with low-density lipoprotein (LDL), since proliferating cells exhibit an increased metabolism of lipoproteins. As an experimental model Greene's melanomas were implanted either into the iris or choroid of albino rabbits. Irradiation at a radiation energy of 80 for iris and 100 J/cm2 for choroidal tumors 3 h after the i.v. injection of BPD-LDL (2 mg/kg) was administered via a laser arrangement with argon-pumped dye-laser, using the slit-lamp. Angiographies and LM/EM histologies were done immediately, and 1, 3, and 14-21 days post-exposure. All 16 treated tumors demonstrated complete regression with a remaining avascular, fibrotic scar. Immediate vascular occlusion within the tumor was seen angiographically, suggesting a direct vascular mechanism. Histologically, two primary mechanisms could be detected: destruction of neovascular endothelial cells and intracellular tumor cell damage. These results indicate that PDT using BPD-LDL complexes may provide an efficient and selective modality for the management of intraocular neoplasms. The availability of new and potent photosensitizers may also lead to broader clinical applications.

AB - Photodynamic therapy (PDT) with its potential for precise localization and absence of severe side effects such as radiation retinopathy may be particularly appropriate for the treatment of intraocular tumors. Benzoporphyrin (BPD), a potent photosensitizer currently in clinical trial, absorbs light at 692 nm, thus allowing sufficient tissue penetration due to minor light absorption in melanin and hemoglobin. The efficiency and selectivity of BPD are significantly pronounced through preassociation with low-density lipoprotein (LDL), since proliferating cells exhibit an increased metabolism of lipoproteins. As an experimental model Greene's melanomas were implanted either into the iris or choroid of albino rabbits. Irradiation at a radiation energy of 80 for iris and 100 J/cm2 for choroidal tumors 3 h after the i.v. injection of BPD-LDL (2 mg/kg) was administered via a laser arrangement with argon-pumped dye-laser, using the slit-lamp. Angiographies and LM/EM histologies were done immediately, and 1, 3, and 14-21 days post-exposure. All 16 treated tumors demonstrated complete regression with a remaining avascular, fibrotic scar. Immediate vascular occlusion within the tumor was seen angiographically, suggesting a direct vascular mechanism. Histologically, two primary mechanisms could be detected: destruction of neovascular endothelial cells and intracellular tumor cell damage. These results indicate that PDT using BPD-LDL complexes may provide an efficient and selective modality for the management of intraocular neoplasms. The availability of new and potent photosensitizers may also lead to broader clinical applications.

KW - benzoporphyrin

KW - intraocular melanoma

KW - low-density lipoprotein

KW - photodynamic therapy

KW - selective delivery

UR - http://www.scopus.com/inward/record.url?scp=0028023777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028023777&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 348

EP - 356

JO - Der Ophthalmologe

JF - Der Ophthalmologe

SN - 0941-293X

IS - 3

ER -